Biotech Values

[oc631]

SNY must believe either that the NVAX platform can enable you to pick a flu strain on VERY short notice

Most seasons we can expect a standard endemic covid and flu market with sufficient lead time to produce a protein-based option. SNY adds scalability and manufacturing that NVAX needed almost as much as they need cash. Yet the days of wallowing over picking the wrong seasonal strain are probably over with mRNA vaccines. Developers can change on a dime and offer a late-season alternative if needed. I'm convinced we are no longer wedded to annual decisions even though current guidance seems to suggest this. If a VOC strain were to emerge late this season it would have put NVAX out of business and now they are backstopped.

Just an observation on NVAX. They filed their 10-Q and the 8-K for their earnings release yet what's notably absent is the 8-K announcing the SNY deal (as of the time of this post). Anyone care to guess why? Anyone think there will be a follow-on offering on Monday?